Top

Journal of Thrombosis and Thrombolysis

Published in:

21-12-2023 | Apixaban

Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies

Authors: Danielle Fredman, Rotem McNeil, Ofir Eldar, Avi Leader, Anat Gafter-Gvili, Tomer Avni

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2024

Abstract

Background

Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban are preferred over vitamin K antagonists for the treatment of venous thromboembolism (VTE). We conducted a systematic review and a meta-analysis to compare the efficacy and safety of rivaroxaban versus apixaban in the treatment of VTE.

Methods

We conducted an electronic search for studies that directly compared treatment with rivaroxaban and apixaban in adult patients with VTE. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled using a fixed-effect model unless significant heterogeneity was present (I² > 40%), then random-effects model was used. The primary efficacy and safety outcomes were recurrent VTE (rVTE) and major bleeding events, respectively.

Results

Nine observational studies were included in our meta-analysis, assessing 24,156 patients for apixaban and 38,847 for rivaroxaban. Pooling of data for our primary efficacy outcome showed a trend towards lower risk of rVTE with apixaban compared to rivaroxaban (RR 0.77, 95% CI 0.57–1.04, I² = 53%). Analysis of our primary safety outcome showed a significantly lower risk of major bleeding with apixaban compared to rivaroxaban (RR 0.68, 95% CI 0.61–0.76, I² = 0%). Apixaban was associated with significantly decreased risk of net clinical harm, clinically relevant non major bleeding (CRNMB) and any bleeding, compared to rivaroxaban (RR 0.75, 95% CI 0.61–0.92, I² = 50%; RR 0.58, 95% CI 0.50–0.67, I² = 7%; RR 0.64, 95% CI 0.59–0.70, I² = 0%, respectively).

Conclusions

Apixaban is associated with a significantly lower risk of major bleeding compared to rivaroxaban for treatment of VTE. Given the limitations of the existing evidence, further interventional studies comparing the two drugs are needed.

Available only for authorised users

Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3(8):1611–1617. https://doi.org/10.1111/j.1538-7836.2005.01415.xCrossRefPubMed

Di Nisio M, van Es N, Büller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060–3073. https://doi.org/10.1016/S0140-6736(16)30514-1CrossRefPubMed

WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, et al (2010) Heart disease and stroke statistics--2010 update: a report from the American Heart Association [published correction appears in Circulation. 2010 Mar 30;121(12):e260. Stafford, Randall [corrected to Roger, Véronique L]] [published correction appears in Circulation. 2011 Oct 18;124(16):e425]. Circulation 121(7):e46–e215. doi:https://doi.org/10.1161/CIRCULATIONAHA.109.192667

Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. https://doi.org/10.1056/NEJMoa1302507CrossRefPubMed

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:https://doi.org/10.1056/NEJMoa1007903

Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest 149(2):315–352. doi:https://doi.org/10.1016/j.chest.2015.11.026

Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405CrossRefPubMed

Ortel TL, Neumann I, Ageno W et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693–4738. https://doi.org/10.1182/bloodadvances.2020001830CrossRefPubMedPubMedCentral

Sindet-Pedersen C, Pallisgaard JL, Staerk L, et al (2017) Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. Sci Rep 7(1):3347. Published 2017 Jun 13. doi:https://doi.org/10.1038/s41598-017-03596-x

10.

Kakkos SK, Kirkilesis GI, Tsolakis IA (2014) Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48(5):565–575. https://doi.org/10.1016/j.ejvs.2014.05.001CrossRefPubMed

11.

Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034CrossRefPubMed

12.

Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894. https://doi.org/10.1111/jth.14219CrossRefPubMed

13.

Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607. https://doi.org/10.1056/NEJMoa1915103CrossRefPubMed

14.

Mantha S, Ansell J (2015) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis 39(2):155–165. https://doi.org/10.1007/s11239-014-1102-5CrossRefPubMed

15.

Cohen AT, Hamilton M, Mitchell SA, et al (2015) Comparison of the novel oral anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 10(12):e0144856. Published 2015 Dec 30. doi:https://doi.org/10.1371/journal.pone.0144856

16.

Mamas MA, Batson S, Pollock KG et al (2022) Meta-analysis comparing Apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation. Am J Cardiol 166:58–64. https://doi.org/10.1016/j.amjcard.2021.11.021CrossRefPubMed

17.

Sterne JA, Hernán MA, Reeves BC, et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. Published 2016 Oct 12. doi:https://doi.org/10.1136/bmj.i4919

18.

Schulman S, Kearon C (2005) Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. doi:https://doi.org/10.1111/j.1538-7836.2005.01204.x

19.

Higgins JPT, Cochrane Collaboration (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken

20.

Brucks EB, Veeravelli S, Halder R et al (2020) Retrospective real-world analysis of the primary safety outcomes in venous thromboembolism of high-risk major bleeding cancer patients receiving therapeutic anticoagulation. Blood 136(Supplement 1):15–16. https://doi.org/10.1182/blood-2020-139641CrossRef

21.

Davis DO, Davis KA (2018) Evaluation of direct-acting oral anticoagulant use in patients with cancer. J Pharm Pract 31(5):441–444. https://doi.org/10.1177/0897190017722873CrossRefPubMed

22.

Dawwas GK, Leonard CE, Lewis JD, Cuker A (2022) Risk for recurrent venous thromboembolism and bleeding with Apixaban compared with rivaroxaban: an analysis of real-world data [published correction appears in Ann Intern Med. 2022 Nov;175(11):1627–1628]. Ann Intern Med 175(1):20–28. doi:https://doi.org/10.7326/M21-0717

23.

Dawwas GK, Brown J, Dietrich E, Park H (2019) Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 6(1):e20–e28. https://doi.org/10.1016/S2352-3026(18)30191-1CrossRefPubMed

24.

Bott-Kitslaar DM, McBane RD, Casanegra AI et al (2019) Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc 94(7):1242–1252. https://doi.org/10.1016/j.mayocp.2018.09.022CrossRefPubMed

25.

Kushnir M, Choi Y, Eisenberg R et al (2019) Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 6(7):e359–e365. https://doi.org/10.1016/S2352-3026(19)30086-9CrossRefPubMed

26.

Sindet-Pedersen C, Staerk L, Pallisgaard JL et al (2018) Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother 4(4):220–227. https://doi.org/10.1093/ehjcvp/pvy021CrossRefPubMed

27.

Trujillo-Santos J, Beroiz P, Moustafa F (2020) Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism [published correction appears in Thromb Res. 2020 Dec; 196:641] [published correction appears in Thromb Res. et al 2021 Dec 208:233]. Thromb Res 193:160–165. https://doi.org/10.1016/j.thromres.2020.06.035CrossRefPubMed

28.

Wysokinski WE, Houghton DE, Casanegra AI et al (2019) Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 94(11):1185–1192. https://doi.org/10.1002/ajh.25604CrossRefPubMed

29.

Aryal MR, Gosain R, Donato A et al (2019) Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 3(15):2381–2387. https://doi.org/10.1182/bloodadvances.2019000572CrossRefPubMedPubMedCentral

30.

Frost C, Song Y, Barrett YC, et al (2014) A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [published correction appears in Clin Pharmacol. 2018 Jun 11;10:71]. Clin Pharmacol 6:179–187. Published 2014 Nov 13. doi:https://doi.org/10.2147/CPAA.S61131

31.

Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488. https://doi.org/10.1182/blood-2002-01-0108CrossRefPubMed

32.

Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520. https://doi.org/10.1200/JCO.19.01461CrossRefPubMed

33.

Brandão GMS, Malgor RD, Vieceli T et al (2022) A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Vascular 30(1):130–145. https://doi.org/10.1177/17085381211002726CrossRefPubMed

Title: Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies
Authors: Danielle Fredman
Rotem McNeil
Ofir Eldar
Avi Leader
Anat Gafter-Gvili
Tomer Avni
Publication date: 21-12-2023
Publisher: Springer US
Keywords: Apixaban
Rivaroxaban
Thrombosis
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2024
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-023-02926-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2024

Outcomes of mechanical thrombectomy in acute stroke patients with atrial fibrillation detected after stroke versus known atrial fibrillation

Antiplatelet therapy in elderly patients with ACS: moving targets need more tailored treatments

External validation of the CHEDDAR score for suspected pulmonary embolism in patients with SARS-CoV-2 infection in an independent cohort

Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis

The association of tumor-expressed REG4, SPINK4 and alpha-1 antitrypsin with cancer-associated thrombosis in colorectal cancer

Elevated factor XI is associated with increased risk of recurrent cerebral venous sinus thrombosis: a cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials